| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
From the Department of Comparative Medicine, Schools of Medicine and Dentistry, University of Alabama at Birmingham, Birmingham, Alabama
Inclusion body myopathy is a progressive muscle disorder characterized by nuclear and cytoplasmic inclusions and vacuolation of muscle fibers. Affected muscle fibers contain deposits of congophilic amyloid, amyloid-ß immunoreactive filaments, and paired helical filaments, all of which are pathological hallmarks of Alzheimer's disease in brain. Accumulations of amyloid-ß and its precursor are thought to play important roles in the pathogenesis of both inclusion body myopathy and Alzheimer's disease. Overexpression of mutant forms of ß protein precursor in transgenic mice by neuron-specific promoters has been reported to cause amyloid deposits in the brain. Here we report that overexpression in transgenic mice of the signal plus 99-amino acid carboxyl-terminal sequences of ß protein precursor, under the control of a cytomegalovirus enhancer/ß-actin promoter, resulted in vacuolation and increasing accumulation of the 4-kd amyloid-ß and the carboxyl-terminus in skeletal muscle fibers during aging. These deposits in transgenic muscle only rarely showed Congo red birefringence. Thus, overexpression of part of ß protein precursor in transgenic mice led to development of some of the characteristic features of inclusion body myopathy. These mice may be a useful model of inclusion body myopathy, which shares a number of pathological markers with Alzheimer's disease.
This article has been cited by other articles:
 |
|
 |
|
  J. Schmidt, K. Barthel, A. Wrede, M. Salajegheh, M. Bahr, and M. C. Dalakas Interrelation of inflammation and APP in sIBM: IL-1{beta} induces accumulation of {beta}-amyloid in skeletal muscle Brain, May 1, 2008; 131(5): 1228 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E-H. Moussa, Q. Fu, P. Kumar, A. Shtifman, J. R. Lopez, P. D. Allen, F. LaFerla, D. Weinberg, J. Magrane, T. Aprahamian, et al. Transgenic expression of {beta}-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology FASEB J, October 1, 2006; 20(12): 2165 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Rosen, V. Veereshwarayya, C. E-H. Moussa, Q. Fu, M. S. Goldberg, M. G. Schlossmacher, J. Shen, and H. W. Querfurth Parkin Protects against Mitochondrial Toxins and beta-Amyloid Accumulation in Skeletal Muscle Cells J. Biol. Chem., May 5, 2006; 281(18): 12809 - 12816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Finch A perspective on sporadic inclusion-body myositis: The role of aging and inflammatory processes Neurology, January 24, 2006; 66(1_suppl_1): S1 - S6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Murphy and T. E. Golde Inclusion-body myositis and Alzheimer disease: Two sides of the same coin, or different currencies altogether? Neurology, January 24, 2006; 66(1_suppl_1): S65 - S68. [Full Text] [PDF]
|
|
|
|
|
|
V. Askanas and W. K. Engel Inclusion-body myositis: A myodegenerative conformational disorder associated with A{beta}, protein misfolding, and proteasome inhibition Neurology, January 24, 2006; 66(1_suppl_1): S39 - S48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, D. Cao, D. W. Garber, H. Kim, and K.-i. Fukuchi Association of Aortic Atherosclerosis with Cerebral {beta}-Amyloidosis and Learning Deficits in a Mouse Model of Alzheimer's Disease Am. J. Pathol., December 1, 2003; 163(6): 2155 - 2164. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. Askanas and W. King Engel Unfolding Story of Inclusion-Body Myositis and Myopathies: Role of Misfolded Proteins, Amyloid-{beta}, Cholesterol, and Aging J Child Neurol, March 1, 2003; 18(3): 185 - 190. [Abstract] [PDF]
|
|
|
|
 |
|
 M. C. Sugarman, T. R. Yamasaki, S. Oddo, J. C. Echegoyen, M. P. Murphy, T. E. Golde, M. Jannatipour, M. A. Leissring, and F. M. LaFerla Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle PNAS, April 30, 2002; 99(9): 6334 - 6339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Rutkove, R. A. Parker, R. A. Nardin, C. E. Connolly, K. J. Felice, and E. M. Raynor A pilot randomized trial of oxandrolone in inclusion body myositis Neurology, April 9, 2002; 58(7): 1081 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Sugarman, T. R. Yamasaki, S. Oddo, J. C. Echegoyen, M. P. Murphy, T. E. Golde, M. Jannatipour, M. A. Leissring, and F. M. LaFerla Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle PNAS, April 30, 2002; 99(9): 6334 - 6339. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
